MVI Vaccine to Be Used in Clinical Trial of a New Combination Approach to Immunotherapy Funded by the Prostate Cancer Foundation and the Movember Foundation

Trial Pairs MVI-816 with a PD-1 Pathway Inhibitor to Treat Metastatic Prostate Cancer Prostate Cancer Foundation/Movember Foundation Award Goes to the University of Wisconsin to Conduct the Clinical Trial August 27, 2014 Madison Vaccines Incorporated (MVI), a clinical stage biopharmaceutical company, today said its lead product candidate MVI-816 (pTVG-HP) will be used in a clinical trial testing a two-pronged immunotherapy …

PD-1 Gene Expression Profiles for Drug Development US Patent Awarded to Vaccine and Gene Institute Florida Scientists

March 2, 2014 The Vaccine and Gene Institute of Florida (VGTI Florida) announced today that the US Patent and Trademark Office awarded VGTI Florida scientists Dr. Rafick-Pierre Sékaly, PhD and Dr. Elias Haddad, PhD U.S. Patent No. 8,647,822 titled ‘Determining whether a test compound modulates PD-1 activity in activated immune cells using gene expression profiles.’ The PD-1 pathway (programmed cell …